Dublin, Calif. – October 27, 2021 –Azure Biosystems, a leading provider of innovative bioanalytical solutions for protein and cell biology, announced today that the company is now authorized to distribute and service the Azure Cielo™ Dx in European Union (EU) countries for in vitro diagnostic (IVD) use. The Azure Cielo™ 3 Dx and the Azure Cielo™ 6 Dx, are real-time PCR systems for 3 and 6 channel nucleic acid detection, respectively. Both systems conform to the EU’s In Vitro Diagnostic Directive (IVDD). These medical device products are also registered with the US FDA for in vitro diagnostic use and have been available for purchase since June 2021.
Since launching in March of 2020, Azure Cielo™ has become part of research labs across world, meeting the global demand for real-time PCR systems. The sensitivity and reproducibility of the Azure Cielo™ have driven the success of Azure Biosystem’s first instrument dedicated to the genomics workflow.
Both Azure Cielo Dx models controlled by a 10.3” touch screen interface, with intuitive software that makes setting up runs and checking run status easy. The compact instrument can transfer data via USB, ethernet or Wi-Fi. For run setup and data analysis, the system comes with Azure Cielo Manager software which offers a complete workflow solution for real time PCR run setup and analysis.
The Azure Cielo™ Dx Systems are expected to begin shipping to Europe in October 2021.
For more information, contact email@example.com, (925) 307-7127
About Azure Biosystems
Azure Biosystems Inc. is an innovative life science platform company that designs, develops, and markets state-of-the-art instruments, including the cSeries imaging platforms. Azure Biosystems’ experienced team has developed 2nd and 3rd generation imaging systems for the life science market, thus applying their technical and market knowledge in creating innovative industry standard setting platforms.
For additional information, please see azurebiosystems.com